Want to see MNPR full AI Analyst Report?

Monopar Therapeutics Inc (MNPR) Stock Forecast & Price Target

582 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MNPR Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Monopar

Therapeutics Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MNPR Stock 12 Month Forecast

Average Price Target

$117.33

▲(6.79% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Monopar Therapeutics Inc in the last 3 months. The average price target is $117.33 with a high forecast of $133.00 and a low forecast of $101.00. The average price target represents a 6.79% change from the last price of $109.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","83":"$83","134":"$134","57.5":"$57.5","108.5":"$108.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":133,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$133.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":117.33333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$117.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$101.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,57.5,83,108.5,134],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.35,110.24615384615385,112.14230769230768,114.03846153846153,115.93461538461538,117.83076923076922,119.72692307692307,121.62307692307692,123.51923076923077,125.41538461538461,127.31153846153846,129.2076923076923,131.10384615384615,{"y":133,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.35,109.04102564102564,109.73205128205127,110.42307692307692,111.11410256410255,111.8051282051282,112.49615384615385,113.18717948717948,113.87820512820512,114.56923076923077,115.2602564102564,115.95128205128205,116.64230769230768,{"y":117.33333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.35,107.78461538461538,107.21923076923076,106.65384615384615,106.08846153846153,105.52307692307691,104.9576923076923,104.3923076923077,103.82692307692308,103.26153846153846,102.69615384615385,102.13076923076923,101.56538461538462,{"y":101,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.93,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.06,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.48,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.47,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.25,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.03,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$133.00

Average Price Target$117.33

Lowest Price Target$101.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Boris Peaker

JonesTrading

$130

Buy

18.32%

Upside

Reiterated

08/12/26

Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile

Jeet Mukherjee

BTIG

$117→$133

Buy

21.05%

Upside

Reiterated

08/12/26

Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), AbSci (ABSI)

Etzer Darout

Barclays

$125

Buy

13.77%

Upside

Reiterated

07/23/26

Barclays Remains a Buy on Monopar Therapeutics Inc (MNPR)

Andres Y. Maldonado

H.C. Wainwright

$105→$125

Buy

13.77%

Upside

Reiterated

07/22/26

Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125

Maxwell Skor

Morgan Stanley

$115

Buy

4.67%

Upside

Reiterated

07/22/26

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Ascendis Pharma (NASDAQ: ASND) and Monopar Therapeutics Inc (NASDAQ: MNPR)

Chad Messer

Lake Street

$103

Buy

-6.25%

Downside

Reiterated

06/30/26

Monopar Therapeutics Inc (MNPR) Gets a Buy from Lake Street

Biren Amin

Piper Sandler

$101

Buy

-8.07%

Downside

Reiterated

06/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

$115

Buy

4.67%

Upside

Reiterated

05/15/26

Leerink Partners Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)

Kristen Kluska

Cantor Fitzgerald

$109

Buy

-0.79%

Downside

Reiterated

05/14/26

Analysts' Top Healthcare Picks: Monopar Therapeutics Inc (MNPR), First Tracks Biotherapeutics Inc (TRAX)

Christopher Raymond

Raymond James

$142→$123

Buy

11.95%

Upside

Reiterated

11/14/25

Monopar downgraded to Outperform from Strong Buy at Raymond JamesMonopar downgraded to Outperform from Strong Buy at Raymond James

Keay Nakae

Chardan Capital

$60→$85

Buy

-22.64%

Downside

Reiterated

09/25/25

Monopar Therapeutics price target raised to $85 from $60 at ChardanMonopar Therapeutics price target raised to $85 from $60 at Chardan

Kemp Dolliver

Brookline Capital Markets

$52→$93

Buy

-15.35%

Downside

Reiterated

09/25/25

Brookline Capital Markets Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Boris Peaker

JonesTrading

$130

Buy

18.32%

Upside

Reiterated

08/12/26

Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile

Jeet Mukherjee

BTIG

$117→$133

Buy

21.05%

Upside

Reiterated

08/12/26

Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), AbSci (ABSI)

Etzer Darout

Barclays

$125

Buy

13.77%

Upside

Reiterated

07/23/26

Barclays Remains a Buy on Monopar Therapeutics Inc (MNPR)

Andres Y. Maldonado

H.C. Wainwright

$105→$125

Buy

13.77%

Upside

Reiterated

07/22/26

Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125

Maxwell Skor

Morgan Stanley

$115

Buy

4.67%

Upside

Reiterated

07/22/26

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Ascendis Pharma (NASDAQ: ASND) and Monopar Therapeutics Inc (NASDAQ: MNPR)

Chad Messer

Lake Street

$103

Buy

-6.25%

Downside

Reiterated

06/30/26

Monopar Therapeutics Inc (MNPR) Gets a Buy from Lake Street

Biren Amin

Piper Sandler

$101

Buy

-8.07%

Downside

Reiterated

06/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

$115

Buy

4.67%

Upside

Reiterated

05/15/26

Leerink Partners Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)

Kristen Kluska

Cantor Fitzgerald

$109

Buy

-0.79%

Downside

Reiterated

05/14/26

Analysts' Top Healthcare Picks: Monopar Therapeutics Inc (MNPR), First Tracks Biotherapeutics Inc (TRAX)

Christopher Raymond

Raymond James

$142→$123

Buy

11.95%

Upside

Reiterated

11/14/25

Monopar downgraded to Outperform from Strong Buy at Raymond JamesMonopar downgraded to Outperform from Strong Buy at Raymond James

Keay Nakae

Chardan Capital

$60→$85

Buy

-22.64%

Downside

Reiterated

09/25/25

Monopar Therapeutics price target raised to $85 from $60 at ChardanMonopar Therapeutics price target raised to $85 from $60 at Chardan

Kemp Dolliver

Brookline Capital Markets

$52→$93

Buy

-15.35%

Downside

Reiterated

09/25/25

Brookline Capital Markets Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Monopar Therapeutics Inc

3 Months

Andres Y. MaldonadoH.C. Wainwright

Success Rate

7/9 ratings generated profit

Average Return

+52.11%

Copying Andres Y. Maldonado's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +52.11% per trade.

1 Year

Kristen KluskaCantor Fitzgerald

Success Rate

7/7 ratings generated profit

Average Return

+107.20%

Copying Kristen Kluska's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +107.20% per trade.

2 Years

Biren AminPiper Sandler

Success Rate

7/7 ratings generated profit

Average Return

+121.47%

Copying Biren Amin's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +121.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MNPR Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MNPR has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MNPR average Analyst price target in the past 3 months is 117.33.

Each month's total comprises the sum of three months' worth of ratings.

MNPR Financial Forecast

MNPR Earnings Forecast

The previous quarter’s earnings for MNPR were -$0.62.

No data currently available

MNPR Sales Forecast

Currently, no sales data available.

MNPR Stock Forecast FAQ

What is MNPR’s average 12-month price target, according to analysts?

Based on analyst ratings, Monopar Therapeutics Inc’s 12-month average price target is 117.33.

What is MNPR’s upside potential, based on the analysts’ average price target?

Monopar Therapeutics Inc has 6.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MNPR a Buy, Sell or Hold?

Monopar Therapeutics Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Monopar Therapeutics Inc’s price target?

The average price target for Monopar Therapeutics Inc is 117.33. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $133.00 ,the lowest forecast is $101.00. The average price target represents 6.79% Increase from the current price of $109.87.

What do analysts say about Monopar Therapeutics Inc?

Monopar Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of MNPR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Monopar Therapeutics Inc (MNPR) Stock Forecast & Price Target

MNPR Analyst Ratings

MNPR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Monopar Therapeutics Inc

MNPR Analyst Recommendation Trends

MNPR Financial Forecast

MNPR Earnings Forecast

MNPR Sales Forecast

MNPR Stock Forecast FAQ

Detailed List of Analyst Forecasts